Cross-Sectional and Longitudinal Patterns of Atrophy in Thalamic and Deep Gray Matter Nuclei in Frontotemporal Dementia

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We acknowledge the use of data collected by the Neuroimaging in Frontotemporal Dementia (NIFD/FTLDNI) initiative, supported by the National Institute on Aging (Grant R01 AG032306) and coordinated through the University of California, San Francisco, Memory and Aging Center. FTLDNI data were disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The primary objective of this initiative was to characterize longitudinal clinical and imaging changes in frontotemporal lobar degeneration (FTLD) and evaluate imaging modalities and biomarkers for diagnostic purposes. This work was additionally supported by the National Institutes of Health - National Institute on Aging (NIH/NIA) Grants R03 AG070750 and R01 AG072669, as well as by the National Institute on Aging Grant R21 AG087392 and the National Institute of Biomedical Imaging and Bioengineering Grant R01 EB032674.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

LONI: https://ida.loni.usc.edu/home/projectPage.jsp?project=NIFD NIFD data use agreement: https://ida.loni.usc.edu/collaboration/access/appLicense.jsp

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes